Nov 12, 2012 | General News, Uncategorized
Chief Scientific Officer, Mike Owens, Ph.D., was quoted in the Wall Street Journal discussing the potential of anti-methamphetamine antibodies to be available in the right amount at the right time. Read the...
May 12, 2012 | Anti-METH ch-mAb7F9, Uncategorized
The first subjects have been successfully dosed in InterveXion’s Phase 1a clinical safety study of ch-mAb7F9 in healthy human volunteers. Expected enrollment is 40 subjects in this escalating dose protocol covering doses from 0.2-20 mg/kg. InterveXion expects to...
Apr 12, 2012 | Anti-METH ch-mAb7F9, Uncategorized
An IND for InterveXion’s chimeric anti-METH monoclonal antibody, ch-mAb7F9, was submitted to FDA in March and became active in early April. Plans for the Phase 1a clinical study in healthy volunteers are being finalized and we expect to begin screening potential...
Jul 15, 2011 | Anti-METH ch-mAb7F9, Grants, Uncategorized
A grant to fund the First in Human, Phase 1a clinical study of anti-METH ch-mAb7F9 was awarded to UAMS and InterveXion. This three year, $3 million, award will be used to test the safety of the chimeric antibody in healthy human volunteers.
Apr 27, 2011 | Anti-METH ch-mAb7F9, Uncategorized
On April 26, 2011 the company had a productive meeting with the FDA to discuss the impending IND application for ch-mAb7F9 as a treatment for chronic METH use. The discussion centered around the toxicology program and antibody characterization techniques. InterveXion...
Oct 1, 2009 | Anti-METH ch-mAb7F9, Grants, Uncategorized
InterveXion has been awarded a two year $3.9 million grant entitled “Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity” by the National Institutes of Health, National Institute on Drug Abuse (NIDA) as part of the American Recovery and...
Sep 30, 2009 | Anti-PCP ch-mAb6B5, General News, Uncategorized
InterveXion met with the FDA on September 29, 2009 to discuss plans for a Phase 1 clinical trial of the PCP antibody ch-mAb6B5. InterveXion’s management team was present with its regulatory consultant from Quintiles, Dr. Raj Kishore, and members of the NIDA management...
Mar 1, 2005 | General News, Uncategorized
Roby Brock – Talk Business Monthly Despite the fact that there are many political allusions to the title of this column, today’s words are about a fledgling business enterprise here in Arkansas. More importantly, they are about the life of a single mother who...
Jan 1, 2005 | General News, Uncategorized
InterveXion Therapeutics, LLC, a company started in the biomedical business incubator at the University of Arkansas for Medical Sciences (UAMS), has received a $3 million grant to conduct clinical trials for the first antibody treatment for addiction to the drug known...
Recent Comments